Wired

The platform is the canonical form of internet business: a two-sided market that facilitates connections between end-users and business customers. Uber connects drivers with riders; Amazon and eBay connect sellers with buyers; TikTok and YouTube connect performers with audiences; social media connects people with something to say with people who want to hear it.

And yet, lax competition law has allowed companies to consolidate, cornering their markets. Consolidated sectors, meanwhile, find it easy to sing with one voice, blocking the passage of unfavorable regulation (there’s still no US national privacy law) or its enforcement (the EU’s General Data Protection Regulation shows that Ireland is even more valuable as a lawless regulation haven than it ever was as a mere tax haven).

Every November, the Global Carbon Project publishes the year’s global CO2 emissions. It’s never good news. At a time when the world needs to be reducing emissions, the numbers continue to climb. However, while emissions have been moving in the wrong direction, many of the underpinning economic forces that drive them have been going the right way. This could well be the year when these various forces push hard enough to finally tip the balance.

Earlier this year, Parkinson’s disease (PD) research entered a new era when the Michael J. Fox Foundation announced a momentous scientific breakthrough—the discovery of a biomarker for PD. It meant that, for the first time ever, we can now pinpoint the earliest known signs of the disease in Parkinson’s patients.

This long-awaited new procedure is called the “alpha-synuclein seeding amplification assay” (SAA), and it’s capable of detecting the misfolded alpha-synuclein in spinal fluid—the wayward protein clearly linked to Parkinson’s. It separates, with a stunning 90 percent specificity, those who have evidence of PD pathology in their cells from those who do not. It does so even before the emergence of symptoms, much like the way high blood pressure or cholesterol levels are used to detect cardiovascular risk long before a heart attack lands someone in the ER.

In 2024, I will walk into a physical space—a restaurant, a hairdresser, an arts venue, an artisanal cheese shop—and instead of being handed a physical piece of paper with some useful information on it, or being told it in words, I will be shown a faded roundel with a QR code on it. I will hold my phone’s camera up to it wearily. Sometimes it will work, but the font on the menu or the information will be small. I’ll have to enlarge it and take my glasses off to read it, because I’ve reached that age. Sometimes it won’t work at all. Sometimes the information on it will be out of date.

In 2024, we will see courts and regulators around the world demonstrate that tech exceptionalism, when it comes to the applicability of legal rules, is magical thinking. The tide has already started to turn on the assumption that law and regulation cannot keep up with technological innovation. But, in 2024, the sea change will come: not through new rules, but by old rules being applied aggressively to new problems.

In the United States, in the absence of federal privacy legislation, regulators have already started to repurpose laws and rules they do have at their disposal to address some of the most egregious examples of Big Tech playing fast and loose with our rights and personal data. In 2023, the US Federal Trade Commission (FTC) continued to expand the regulatory heft of consumer protection regulations.

“It might be the best time for any kind of business in any industry to raise money for all of history, like since the time of the ancient Egyptians,” an excitable Stuart Butterfield, CEO of Slack, told Farhad Manjoo in The New York Times in 2015.

This was no exaggeration. While interest rates remained close to zero, venture capital funds raised more money than ever and exited their investments at some of the highest valuations ever witnessed.

If you buy something using links in our stories, we may earn a commission. This helps support our journalism. Learn more. Please also consider subscribing to WIRED

In the decades to come, 2023 may be remembered as the year of generative AI hype, where ChatGPT became arguably the fastest-spreading new technology in human history and expectations of AI-powered riches became commonplace. The year 2024 will be the time for recalibrating expectations.

The ocean is Earth’s defining feature. Two of the most famous photographs of all time stamped that indelibly on our minds: Earthrise (1968) and The Blue Marble (1972), both taken during the Apollo missions to the moon. Once you have seen our fragile blue planet hanging in space, you can’t unsee it.

The ocean is an engine driven by sunlight, one that shifts and swirls as it carries energy, nutrients, and life around the planet in intricate patterns both large and small. The way it turns affects all our lives. It’s not a coincidence that Iceland happens to have rich fishing grounds, or that Britain is randomly warmer than Canada at the same latitude, or that luck of the draw means that the North Sea is green rather than blue.

When the pandemic hit, Gen Z-ers—born between 1997 and 2012—were just entering adulthood. After enduring a particularly difficult time during lockdowns, today they face an acute mental health crisis. As a result, in 2024, many will be asking more from their work life.

When my research team at Harvard University interviewed 80 Gen Z college students, we noticed an overwhelming desire to double down on their efforts to live authentically. This means doing work they are passionate about, building meaningful bonds with peers, making public their private selves—whether that means their tastes and preferences, their sexual identity, their past traumas—to those who surround them, as and when they are so moved.

At the end of 2023, we witnessed an important moment in the history of medicine: For the first time, the US Food and Drug Administration approved a therapy that uses Crispr gene editing. This new therapy was developed by Crispr Therapeutics and Vertex Pharmaceuticals to treat sickle cell disease, an ailment caused by a single-letter mutation in the genetic code that has been long understood but was neglected by the research community for decades.